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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
bitemporal ECT is more effective than bifrontal ECT in the treatment of adults with major
depressive disorder.
STUDY DESIGN: Review of three published randomized controlled trials, all English language.
All RCTs were published after 1999 and studied patients older than 17 years old.
DATA SOURCES: Three randomized control trials were found using PubMED, OVID, and
Medline. Articles were selected based on relevance and that the outcomes of the studies mattered
to patients.
OUTCOME(S) MEASURED: Hamilton Rating Scale for Depression- 24 item completed by
practitioner.
RESULTS: The results of the Kellner6 study was that bitemporal ECT placement had an average
change in HRSD-24 score of 22.4 points, from 33.7 to 11.3 (P<0.0001), and a remission rate of
64% (95% CI 53-75%). Bitemporal ECT was 3% more effective than bifrontal ECT for treating
depression. 6 The Bailine2 study concluded that bitemporal ECT placement had an average
change in HRSD-24 score of 22.7 points, from 27.7 to 5.0 and a remission rate of 95.8%.
Bifrontal ECT was 4.2% more effective than bitemporal ECT for treating depression. 2 The
Ranjkesh8 study reported that bitemporal ECT placement had an average change in HRSD-24
score of 24.3 points, from 32.1 to 7.8, and a remission rate of 100%. There was no difference in
effectiveness when comparing bitemporal ECT to bifrontal ECT.8
CONCLUSIONS: The results of the three randomized controlled trials found that bitemporal
ECT and bifrontal ECT are effective in the treatment of adults with major depressive disorder.
The analysis of the three randomized controlled trials is inconclusive to whether bitemporal is
more effective than bifrontal ECT in treating adults with major depressive disorder.
KEY WORDS: ECT, depression, bitemporal
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INTRODUCTION
Electroconvulsive therapy (ECT) is predominately used to treat severe depression. After
the administration of general anesthesia, a small electric current is given via electrodes to the
patient to produce a generalized cerebral seizure. 1 This paper evaluates three randomized
controlled trials (RCTs) comparing the effectiveness of bitemporal electrode ECT placement for
the treatment of severe depression with other electrode ECT placements.
This topic/question is relevant to practicing PA and patients because of the high
prevalence and significant number of health care visits each year for major depressive disorder.
Major depression affects 16.6% of the US population and is the leading cause of disability in
Western countries between ages 15-44 years old. 2 ECT costs vary but range from $300-$800 per
treatment. After eight sessions (average number to completion), the total cost is $2400-$6400 per
patient. 3 8.0 million people visited a physician office or ER with major depressive disorder as
the primary diagnosis in 2009-2010. 4
The exact cause of depression is unknown but is thought to be a combination of genetics,
dysregulation of neurotransmitters (specifically serotonin, norepinephrine, and dopamine),
immunologic abnormalities, and social/psychological factors. 5 Symptoms of depression include
depressed mood, anhedonia, physical symptoms (fatigue, appetite problem, psychomotor
changes, sleep disorder), and psychological symptoms (difficulty concentrating, guilt, thoughts
of death). 5
The usual methods of treatment for major depression include a combination of
psychotherapy and pharmacology. The first line pharmacological agents are selective serotonin
reuptake inhibitors (SSRI) that include fluoxetine, paroxetine, sertraline, citalopram,
escitalopram. Alternative antidepressant agents are serotonin norepinephrine reuptake inhibitors
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(SNRIs) :venlafaxine, duloxetine; noradrenergic and specific serotonergic antidepressant
(NaSSa): mirtazapine; norepinephrine dopamine reuptake inhibitors (NDRI): buproprion; and
tricyclic antidepressants (TCA); amitriptyline, and nortriptyline 5.
Select patients have refractory cases of depression that cannot be managed by the
treatment options mentioned above. The method of treatment is being proposed because the use
of ECT has been shown to be effective in the treatment of major depressive disorder in adults
who have not benefited or been treated adequately with traditional psychotherapy and
pharmacology.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not bitemporal
ECT is more effective than bifrontal ECT in the treatment of adults with major depressive
disorder
METHODS
The population studied was men and women with severe depression older than 17 years
of age. The intervention studied was bitemporal ECT. All three randomized control studies being
used compared bitemporal ECT to bifrontal ECT therapy. Outcomes were measured on the
severity of depression as rated on the Hamilton Depression Score that was completed by a
practitioner.
Keywords used in the search to find these studies were ECT, bitemporal, and depression.
All articles were published in peer-reviewed journals and in English. The author researched the
articles via Medline, PubMed, and OVID search engines. Articles were selected based on
relevance and that the outcomes of the studies mattered to patients (POEMs). The inclusion
criteria included studies that were RCTs published after 1999. The exclusion criteria included pts
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under the age of 17 years old. Summary statistics were reported or used RBI, ABI, NNT, and pvalues.
Table 1 - Demographics & Characteristics of included studies
Study
Type #Pts Age Inclusion
Exclusion Criteria
Criteria
Ranjkesh RCT 45
>18 Score greater
history of ECT during the
6
(2005)
than 16 on the
preceding 3-month
HDRS score
period, taking
greater, more
nonbenzodiazepine
than 2 days'
anticonvulsants,
antidepressant
lidocaine, theophylline, or
discontinuation lithium, a history of
for a wash-out
psychiatric disorders not
period
related to a mood disorder

Bailine7
(2000)

RCT

58

>17

Kellner 8
(2010)

RCT

230

2087

score higher
than 17 on the
HRDS, score
higher than 2 on
the first item
(sad mood),
score higher
than 24 on the
standardized
Mini-Mental
State
Score higher
than 21 on the
HRDS, ability
to cooperate in
detailed
neuropsychologi
cal testing,
referred for
ECR for
primary major
depressive
disorder or
bipolar disorder,
w or w/o
psychosis

W/D

Interventions

6

Bitemporal,
Right
unilateral,
bifrontal ECT
placement

10

Bitemporal,
bifrontal ECT
placement

History of any psychiatric 63
disorder not related to a
mood disorder, a mood
disorder that was not
depression before this
episode of depression, any
disease affecting
cognition, substance
abuse in the last 6 months,
medical conditions
contraindicating ECT,
ECT in the last 6 months,
MMSE >21

Bitemporal,
Right
unilateral,
bifrontal ECT
placement

history of any other
psychiatric disorder not
related to a mood
disorder, ECT within the
past 6 months, use of
psychotropic medication,
except up to 3 mg/day of
lorazepam as needed for
agitation or anxiety
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OUTCOMES MEASURED
Study outcomes measured were the severity of depression. Outcomes were measure by
using the Hamilton Rating Scale for Depression- 24 (HRSD-24) item completed by practitioner.
Practitioner assigns a number to the severity of symptoms. Symptoms assessed include:
depressed mood, feelings of guilt, suicide, insomnia early, insomnia middle, insomnia late, work
and activities, psychomotor retardation, agitation, anxiety (psychological), anxiety somatic,
somatic symptoms (gastrointestinal), somatic symptoms general, genital symptoms,
hypochondriasis, loss of weight, insight, diurnal variation, depersonalization and derealization,
paranoid symptoms, obsessional and compulsive symptoms.
Kellner et al measured outcome was the severity of depression using continuous HRDS24 scores approximately three times a week and a single end of treatment HRSD-24 score within
24-36 hours of the final ECT. 8
Bailine et al measured outcomes were the severity of depression using the HRSD-24
score, severity of symptoms in depression using the Clinical Global Impression scale, and
cognitive impairment using the standardized Mini Mental scores at baseline and 24 hours after
each treatment. 7
Ranjkesh et al measured outcomes were the severity of depression using the HRSD-24
score, and cognitive impairment using the standardized Mini Mental scores. These were assessed
before receiving the initial ECT session, before the fourth ECT session, and on day after the
eighth ECT session. A clinical psychologist unaware of the ECT electrode placement performed
the tests at approximately 8 am. 6
RESULTS
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The three studies compared bitemporal ECT to bifrontal ECT placement. All trials were
done on adults > 17 yo.
The Kellner8 study was a randomized control, double blind, comparison trial that
randomized 230 subjects into groups receiving right unilateral ECT (77 patients), bifrontal ECT
(81 patients), and bitemporal ECT (72 patients). Each patient was treated with their assigned
ECT electrode placement until they reached pre-specified remission criteria, then patients were
followed naturalistically for 2 months. Of the 230 participants who entered the trial, 63 (27.4%)
exited the study early due to confusion/cognitive impairment, ECT not working, non cognitiveside effect, and improvement in condition. “Worst-case” analysis was not done on the
participants that did not complete the trial. There was no statistically significant difference
between the participants in all three trial groups as determined by the general linear model.
(P<0.0001). The mean age of the participants was 53 years old, 63.5% female, and 95.5 % of
participants were white. In regards to the severity of their depression, the participants initially
had a mean HRSD-24 baseline of 34.6, the average length of their current depressive episode
was 2.4 years, and they had an average of 4.6 psychiatric admissions. Patients were treated with
ECT until pre-specified remission criteria and were assessed with the HRSD-24 at baseline, the
fourth ECT, and the last ECT, 1 week after the last ECT, and 2 months after the last ECT. After
completion of the study, all three electrode placements had statistically significantly decrease in
symptoms of depression. Right unilateral ECT placement had an average change in HRSD-24
score of 21.0 points, from 34.9 to 13.9 (P<0.0001), and a remission rate of 55% (95% CI 4366%). Bifrontal ECT placement had an average change in HRSD-24 score of 23.4 points, from
35.1 to 11.7 (P<0.0001), and a remission rate of 61% (95% CI 50-71%). Bitemporal ECT
placement had an average change in HRSD-24 score of 22.4 points, from 33.7 to 11.3

5
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(P<0.0001), and a remission rate of 64% (95% CI 53-75%). Table 2 shows the treatment effects
of bitemporal ECT on the symptoms of depression, when compared to bifrontal ECT as control.
Relative benefit increase (RBI) was calculated to be 0.05. Absolute benefit increase (ABI) was
calculated to be 3%. Numbers needed to treat (NNT) was calculated as 33, indicating that 33
patients need to be treated with bitemporal ECT rather then bifrontal ECT to see one more
patient have remission of depressive symptoms 8 weeks after their last ECT treatment. 8
Table 2: Treatment effect of bitemporal ECT on depression
CER

EER

RBI

ABI

NNT

P

61%

64%

0.05

3%

33

0.0001

The Bailine7 study was a randomized control, double blind, comparison trial that randomized 58
subjects into groups receiving bifrontal ECT (24 patients), and bitemporal ECT (24 patients), 10
patients did not complete the study due to medical problems unrelated to ECT, two require
antipsychotic medication, two discharged before completing the study. ‘Worst-case’ analysis was
not done on the participants that did not complete the trial by the 12th treatment, 24/24 patients in
the bifrontal ECT group and 23/24 patients in the bitemporal ECT group met remission criteria
for depression. There was no statistically significant difference between the participants of each
group as analyzed with chi-square tests for categorical variables and t test for continuous
variables . (P= 0.90). The mean age of the participants was 52.86 years old and 53.3% female. In
regards to the severity of their depression, the participants initially had a mean HRSD-24
baseline of 28.3. Patients received ECT three times a week until they met remission criteria. If a
patient did not meet the criteria by their 12th treatment they were considered a failure. After
completion of the study, both electrode placements had statistically significantly decrease in
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symptoms of depression. Bifrontal ECT placement had an average change in HRSD-24 score of
22.2 points, from 28.1 to 6.7 (P- 0.09), and a remission rate of 100%. Bitemporal ECT placement
had an average change in HRSD-24 score of 22.7 points, from 27.7 to 5.0 and a remission rate of
95.8%. Table 3 shows the treatment effects of bitemporal ECT on the symptoms of depression,
when compared to bifrontal ECT as control. Relative benefit increase (RBI) was calculated to be
-0.04. Absolute benefit increase (ABI) was calculated to be -4.2%. Numbers needed to treat
(NNT) was calculated as -24, indicating that for every 24 patients treated with bitemporal ECT
one fewer would have remission of depressive symptoms by their 12th ECT treatment compared
to bifrontal ECT treatment. 7
Table 3: Treatment effect of bitemporal ECT on depression
CER

EER

RBI

ABI

NNT

P

100%

95.8%

-0.04

-4.2%

-24

0.77

The Ranjkesh6 study was a randomized control, double blind, comparison trial that randomized
45 subjects into groups receiving bifrontal ECT (15 patients), right unilateral ECT (15 patients)
and bitemporal ECT (15 patients), 6 patients did not complete the study, 2 from the bifrontal
group, 1 from the bitemporal group, and 3 from the right unilateral group. “Worst-case” analysis
was not done on the participants that did not complete the trial. There was no statistically
significant difference between the participants of each group as analyzed with chi-square tests
and one way analysis of variance (P> 0.05). The mean age of the participants was 34.7 years old
and 61.5% female. In regards to the severity of their depression, the participants initially had a
mean HRSD-24 baseline of 34.7. Patients received at least 8 ECT treatments, with the final
HRSD-24 score recorded for the study completed after that treatment. After completion of the
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study, all electrode placements had statistically significantly decreased the symptoms of
depression according to the HRSD-24 score. Bifrontal ECT placement had an average change in
HRSD-24 score of 25.7 points, from 35.0 to 9.3 (P- 0.09). Right unilateral ECT placement had
an average change in HRSD-24 score of 24.8 points, from 32.2 to 7.4, 100% remission.
Bitemporal ECT placement had an average change in HRSD-24 score of 24.3 points, from 32.1
to 7.8, 100% remission. All three methods demonstrated effectiveness in reducing HRSD-24
scores over time and treating depression, with no significant difference in one method over
another (P > 0.05). Table 3 shows the treatment effects of bitemporal ECT on the symptoms of
depression, when compared to bifrontal ECT as control. Relative benefit increase (RBI) was
calculated to be 0. Absolute benefit increase (ABI) was calculated to be 0%. Numbers needed to
treat (NNT) was calculated as 0, indicating that neither ECT electrode placement will cause more
negative or positive outcomes to a patient. 6
Table 4: Treatment effect of bitemporal ECT on depression
CER

EER

RBI

ABI

NNT

P

100%

100%

0

0%

0

> 0.05

DISCUSSION
This selective evidence based medicine review investigated three randomized controlled
trials to determine whether or not bitemporal ECT is an effective treatment for depression. All
three studies were analyzed by comparing bitemporal ECT to bifrontal ECT.
All three trials concluded that when analyzed individually bitemporal ECT, and bifrontal
ECT were effective in treating depression. When the analysis was done comparing bitemporal
ECT to bifrontal ECT the results were inconclusive. There was a lack of studies comparing
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bitemporal ECT to placebo in the initial search for studies, which made it necessary to compare
bitemporal ECT to bifrontal ECT.
The results of the Kellner8 study are generalizable to adult patients with major depression
and suggests that bitemporal ECT is very effective at treating depression. However the RBI of
0.05 is small and suggests that it is not much more effective than bifrontal ECT. The ABI
suggests that 3% of patients receiving bitemporal ECT will have improvement of their
depression when compared to patients receiving bifrontal ECT. Some limitations of this study
include a high drop out rate (27.4%), and the frequency of data collection (5 collections). This
study did conclude that bitemporal ECT has more rapid symptom reduction when compared to
bifrontal, and right unilateral ECT. 8
The results of the Bailine7 study are generalizable to adult patients with major depression.
The study concluded that both bitemporal and bifrontal ECT were efficacious in treating
depression. In this review, comparing bitemporal and bifrontal ECT an ABI of -4.2% suggests
that bifrontal ECT will have more improvement on depression when compared to bitemporal
ECT. The p-value in this study was 0.77, suggesting the results are not statistically significant.
Some limitations of this study include a small sample size (58), and a high drop out rate
(17.2%).7
The results of the Ranjkesh6 study are generalizable to adult patients with depression. The
study concluded that bitemporal and bifrontal ECT are effective at treating depression in adults,
both with 100% effectiveness. When comparing bitemporal to bifrontal ECT the RBI, and ABI
were both 0. This is stating that there is no difference in efficacy when choosing bifrontal to
bitemporal ECT. The p-value in this study was >0.05 making the results not statistically
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significant. Some limitations of this study include small sample size 45, and high drop out rate
(13.3%).6
CONCLUSION
When analyzed without comparison, bitemporal ECT is effective at treating major depression.
When bitemporal ECT is compared to bifrontal ECT the results are conflicting. Future studies
are warranted comparing bitemporal ECT to placebo. A study of this design would be limited by
not being able to be double blinded because it is very obvious to both the patient and clinician if
a patient received ECT or not.
.

go

References
1. Kellner C. Overview of electroconvulsive therapy (ECT) for adults. UpToDate. 2014;Topic
1709 Version 21.0:10/5/2014.
2. Primm A, Gomez M, Cohen D. Chapter 52. depression in diverse populations & older adults.
In: Current diagnosis & treatment in family medicine, 3e. ; 2001. Accessed 10/5/2014.
3. American Psychiatric Association. Electroconvulsive therapy
(ECT). http://www.ect.org/resources/apa.html. Updated 2011. Accessed 10/2014, 2014.
4. CDC/National Center for Health Statistics. FastStats: Depression. Center for Disease Control
Web site.http://www.cdc.gov/nchs/fastats/depression.htm. Updated 2014. Accessed 10/5, 2014.
5. Cole SA, Christensen JF, Raju Cole M, et al. Chapter 22. depression. In: Feldman M.D. CJF,
ed. Behavioral medicine: A guide for clinical practice, 3e. ;
2008. http://accessmedicine.mhmedical.com/content.aspx?bookid=373&Sectionid=39732021.Ac
cessed 10/5/14. October 5, 2014.
6. Ranjkesh F, Barekatain M, Akuchakian S. Bifrontal versus right unilateral and bitemporal
electroconvulsive therapy in major depressive disorder. J ECT. 2005;21(4):207-210. doi:
00124509-200512000-00005 [pii].
7. Bailine SH, Rifkin A, Kayne E, et al. Comparison of bifrontal and bitemporal ECT for major
depression. Am J Psychiatry. 2000;157(1):121-123.
8. Kellner CH, Knapp R, Husain MM, et al. Bifrontal, bitemporal and right unilateral electrode
placement in ECT: Randomised trial. Br J Psychiatry. 2010;196(3):226-234. doi: 196/3/226
[pii]; 10.1192/bjp.bp.109.066183 [doi].

